A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs ZEN 3694 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Zenith Epigenetics Corp
  • Most Recent Events

    • 13 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top